{"code":0,"count":0,"data":{"conts":"

CYBERKNIFE M6 Foshan's First CyberKnife

Tumor Treatment 「 Black Technology 」

The World's Only Robotic Radiosurgery System for Tumor Ablation

CyberKnife is the world's first fully automated robotic stereotactic body radiotherapy(SBRT) system, representing the pinnacle of conformal radiotherapy technology. ltdelivers highly precise and personalized treatment solutions for most solid tumors through-out the body. installed at the Foshan Fosun Hospital in Guangdong Province, the newlyadvanced CyberKnife M6 offers efficient tumor ablation with just 1-5 treatment sessions.The procedure is minimally invasive, with no incisions, no bleeding, no anesthesia, and ispainless, with minimal side effects. To a certain extent, it can replace or even surpassconventional surgery.

\"4ba333a0-adc6-46c8-985f-4b0794b733b6.png.jpg\"/

Foshan CyberKnife Center

The Foshan CyberKnife Center is the first tumor treatment platform in Foshan to introduce theworld's most advanced stereotactic radiosurgery robot-CyberKnife (6th Generation). it wasfounded by Dr. Yang Jun, the North American standardlsetter for CyberKnife quality control,who returned to China to personally establish the center. Following the installation ofCyberKnife, stereotactic radiosurgical treatment has been applied to most solid tumorsthroughout the body. Under the leadership of Dr. Yang Jun, the Center quickly assembled ahighly skilled multidisciplinary team of domestic and international experts. By employingcuttingledge treatment techniques, it has become a high level clinical and research centerintegrating screening, diagnosis, and treatment.

\"5ae55539-6e00-4650-a76f-06ec27b8ae63.png.jpg\"/\"cd64abde-04d1-496b-853a-f4fe570e576e.png.jpg\"/

International Standard Equipment+ Robust Medical Platform

The Foshan CyberKnife Center is located within atoplranked public hospital in the province and ispart of the JCl accredited, National GradelllClassA Foshan Fosun Chancheng Hospital. Withnearly 60years of heritage in international standardtreatment equipment and a strong platform oftechnical expertise and services, we bring newhope to more patients.

\"61FD434B-2A65-4016-9780-29F9FD62F510.jpg\"

International Pioneer of CyberKnife-Founder of Foshan CyberKnife Center

Dr. Yang Jun Director, Foshan cyberknife center

. Ph.D. in Biomedical Engineering, Medical lmaging Processing and Medical Physics, University of Miami, USA

. Developer of international CyberKnife quality control standards

. Over 6,000 CyberKnife treatment cases

Dr. Yang is a renowned ChineselAmerican medical physicist. in 2003, he joined the Cyberknife Center at theUniversity of Miami, participating in the establishment of the Philadelphia Cyberknife Center and directly took part inthe treatment of approximately 6,000 Cyberknife patients. In 2013, he became Chief Medical Physicist at AllianceOncology--the largest SBRT network in North America-overseeing and managing Cyberknife technology, clinicapractice, and research across 34 treatment centers and 16 CyberKnife units. He serves as Clinical AssociateProfessor at Drexel University, Visiting Professor at Fudan University, Board Member of The Radiosurgery SocietyMember of the AERO (cyberknife User Group), and member of multiple North American medical physics andradiation oncology societies. He is an expert instructor for TG277 (CyberKnife Physics Workshop), a contributor toTG135 (Cyberknife Quality Assurance guidelines), and serves on the International Advisory Board for the journal ofApplied Clinical Medical Physics and as Editorial Board Member for the Journal of Radiation Therapy.

\"Dr

China's Leading Authority on CyberKnife Therapy

Over 12,000 Cases Treated

Dr. Enmin Wang Chief Physician, Foshan CyberKnife Center

· Former Director, CyberKnife Center, Huashan Hospital Affiliated to Fudan University

· China's First Doctorate in Gamma Knife Therapy

· Deputy Director, Committee of Neuro-Radiosurgery, World Federation of Chinese Neurosurgeons

 · Chief Editor of China's Most Authoritative Monograph on CyberKnife: CyberKnife Radiosurgery

Expert in using CyberKnife for treatment of small acoustic neuromas, meningiomas, pituitary adenomas, postoperative residual chordomas, skul base tumors, brain metastases, arteriovenous malformaions (AVMs). jugular foramen tumors, early-stage lung cancer, liver cancer, pancreatic cancer and spinal metastases.



\"25eb4e9b-cd0c-40b2-9347-b42fd3e27d17.png.png\"/

Sponsored by the Chinese government foroverseas study, trained at National Hospital,University College London, UK(2000)


\"2816645a-70c2-487b-a308-68bf85828c52.png.png\"/

Surpassed 10,000 CyberKnifetreatment cases personally performed(2020)


\"0d1b3a99-f40d-44ca-b8c3-3531c428fe9d.png.png\"/

Chief-edited monograph“CyberKnifeRadiosurgery"officially published(2024)


\"20298f53-80e2-4137-b5d1-43c42a102a08.png.png\"/

Joined Foshan CyberKnife Center andbegan consulting at Foshan FosunChancheng Hospital(2024)

The 6 Major Advantages of Cyberknife

     Foshan's only Cyberknife unit     

     Authoritative Proof     

The choice of millions, validated by over 20 years of clinical practice

For more than two decades, a wealth of global clinical cases, data, and authoritative studieshave proven that CyberKnife can treat most solid tumors with outstanding cancer controlrates and minimal long-term side effects.

      Guideline Recommended     

A replacement for surgery, and even superior for certain conditions

Stereotactic Body Radiation Therapy (SBRT), of which CyberKnife is a prime example, caneffectively control local tumor growth, For some conditions, it can replace or even surpasssurgical treatment.

     Wide Range of Applications     

Applicable to most solid tumorsthroughout the body

CyberKnife can treat most solid tumors, including benign and malignant intracranial tumors.functional disorders (like trigeminal neuralaia), head and neck tumors, spinal tumors. lungcancer, breast cancer, liver cancer, pancreatic cancer, adrenal tumors, prostate cancer, andcervical cancer. lt is particularly adept at treating tumors that move, overcoming the chal-lenges posed by tumor and organ motion caused by respiration and bladder filling.

     High Local Control Rate     

Sub-millimeter precision protects normal tissues

Delivers a high dose of radiation with hair-thin (0.1mm) precision to the tumor. With minimaltreatment error, it maximally protects surrounding organs and tissues, reduces the risk ofside effects, and ensures excellent long-term tumor control.

\"c6dedb3f-33ce-469e-9f2d-f7d9a50f66c6.png.png\"/

     Real-time Tracking      

Adaptive tracking technology preciselylocks onto moving tumors

CyberKnife is the only radiation therapy system that can track tumor motion in real-time. ltemploys five different tumor tracking technologies for various conditions, continuously verifyingand locking onto the tumor's position under image guidance. During treatment, the radiation beamautomatically follows the tumor's movement in sync, allowing the patient to simply lie still andcomfortably maintain a high level of treatment accuracy.

\"546f1765-4a87-4b29-9b2f-d5ab37d0dd91.png.png\"/

     Outpatient Treatment     

Safe and efficient 

1-5 sessions 15-30 minutes each

No anesthesia, no incision, no blood loss, no pain, and no hospitalization required. Thenon-invasive treatment can be completed on an outpatient basis. Patients can quicklyreturn to their daily life and work after treatment.

05 Application of CyberKnife in Brain Tumors

Precisely Targeting Brain Tumors

A New, Non-invasive Direction for Tumor Treatment

\"5bd942eb-94e3-4ec9-89c9-c54de4ed20c9.png.jpg\"/

The brain's structure is delicate and complex, and tumorlesions are often located in tricky,   hard-to-treat areas. CyberKnife has become the treatment of choice for somebrain tumors,   delivering an optimal dose of radiation withsub-millimeter precision. Under continuous   imageguidance, it avoids sensitive regions and normal tissues.providing maximum   protection to healthy brain tissue whilecompleting the treatment non-invasively and   painlessly.

CyberKnife has unparalleled advantagesin treating brain tumors and brain metastases

.  High cancer control rate

.  Low incidence of common cognitive side effects

.  Equally applicable for patients who havepreviously undergone brain radiotherapy

.  No surgery, non-invasive, no headframe fixation required

.  No need to interrupt chemotherapy orimmunotherapy

.  The process is comfortable and does notaffect normal life and activities

Cyberknife's PreciseNon-invasive Treatmentfor Trigeminal Neuralgia

\"d93aa4b8-e5ae-4f17-8787-2d6bf8de72b4.png.png\"/

The unpredictable, severe pain caused by the trigeminalnerve can be emotionally distressing and significantlyimpact a patient's daily life. Clinical evidence shows thatCyberKnife can precisely irradiate the nerve, interruptingthe pain signals transmitted to the brain and effectivelyrelieving trigeminal neuralgia.

A long-term follow-up study, "Robotic lmage-Guided Radiosurgery for Trigeminal Neuralgia: Results after 10 Years," on maleand female patients with rigeminal neuralcia (TN), showed that Cyberknife provides lasting relief from the severe pain causedby TN. A second course of treatment is beneficial for patients who did not respond to the first treatment or who experienced arecurrence. This research paper was awarded Best Clinical Paper at the 2022 Radiosurgery Society(RSS) Conference.

Brain Disease Case Study 06

Cerebral Arteriovenous Malformation(AVM)

Female patient with intracranial cerebral AVM presenting with hemorrhage and self-reported dizziness. Afterthree endovascular embolization procedures, the AVM nidus remained patent with recurrent hemorrhages,posing significant life-threatening risks beyond chronic symptoms and sequelae.

Treatment Plan

Fractionation: 8 Gy per fraction x 3 fractions

Prescription dose: 8 Gyx 3F|Prescription isodose line: 75% Total beams: 203

\"10334c62-885d-4eab-afee-fee9e438eee0.png.png\"/

Results and Follow-up

\"ca63a1cd-4672-4e65-a083-b87d45092306.png.png\"/

The patient achieved complete resolution of dizziness following CvberKnife treatment without adverse effects.Six-month MRl/MRA follow-up demonstrated significant nidus bed reduction, near-complete occlusion ofmalformed vasculature, and absence of new hemorrhagic foci. Prognostic assessment indicates continuednidus regression toward complete obliteration over time.

Brain Disease Case Study 07

      Meningioma     

Male patient with meningioma deemed medically inoperable due to comorbidities. Following 5-fractionCyberKnife radiotherapy, significant symptomatic improvement was achieved. Six-month follow-up MRl demon-strated central tumor necrosis with liguefactive changes and absence of contrast enhancement. Treatment waswell-tolerated without disruption to activities of daily living during or after therapy.

Treatment Plan

Fractionation: 5 Gy per fraction x5 fractions  |  Prescription dose: 5 Gy x 5F

Prescription isodose line:72% |  Total beams:262

\"db23865f-b44d-4c55-9558-e72de2c19356.png.png\"/

Results and Follow-up

\"a16e9dff-97a3-45e0-8738-913529199e62.png.png\"/

Brain Disease Case Study 08

       Parkinson's Disease      

70-year-old male with 10-year history of medically refractory Parkinson's disease. Symptoms include turningdifficulty, freezing of gait, hypomimia (masked facies), Dysarthria, sialorrhea and handwriting tremor.

Treatment Plan

Fractionation: 26 Gy per fraction x 3 fractions  |  Prescription dose: 26 Gy x 3F

Prescription isodose line:85%  |  Total beams: 94

\"ad1cca8c-4059-49b0-b725-a1ef72d4be02.png.png\"/

\"cd571333-71f5-40dd-8963-c1ea9fd4b54e.png.png\"/

Results and Follow-up

.  Post-treatment day 2: Significant improvement in gait stability, restored turning ability, and allevia-tion of hypomimia were observed.

.  9-month follow-up: Marked global reduction in Parkinsonian symptoms with sustained ambulatoryimprovement and reduction in handwriting tremor amplitude.

09 Application of Cyberknife in Lung Tumors

Pinpointing Lung Tumors

  Dynamically Tracking the Lesion  

\"2248f71f-cb34-4875-9fc6-d4567f1d5473.png.png\"/

CyberKnife is the first and only radiation therapy system that can overcome tumor displacementcaused by factors such as patient breathing, coughing, and organ motion during treatment. it automat.ically detects and corrects the position, tracking and locking onto the tumor lesion in real-timethroughout the entire session, and continuously delivers treatment with sub-millimeter precision.

Clinically Proven Advantages of CyberKnifefor Lung cancer Treatment:

· Sianificantly reduces toxic side effects, such as shortness of breath, dificulty swallowing, or sorethroat.

· Provides an excellent non-invasive treatment option for patients who are inoperable or for whomsurgery is difficult.

· Medical literature shows that compared to surgery for early-stage lung cancer, Stereotactic BodyRadiation Therapy (SBRT) is better tolerated and results in longer overall survival.

· For the displacement of lung tumors caused by respiration, CyberKnife can track and lock onto thetumor, ensuring precise high-dose irradiation while minimizing side effects.

· Patients do not reauire restraints or breath-holding technigues, the process is comfortable and doesnot disrupt daily activities during the treatment period.

· The treatment course is short and efficient, requiring only 3-5 sessions over 1-2 weeks

· Stereotactic Body Radiation Therapy (SBRT) is a surgical alternative. lt can be used to treatearly-stage or inoperable non-small cell lung cancer (NSCLC), peripheral lung tumors, and centrallylocated or chest wall-adiacent lung tumors surrounded by sensitive structures.

Lung Tumor Case Study 10

Squamous Cell Carcinoma of the Left Upper Lung

73-year-old male with locally advanced peripheral lung cancer.

\"4f80f3f7-3531-4dd6-8a8e-ae1d1c444b57.png.jpg\"/

Treatment Plan

CyberKnife SBRT to left lung lesion:

Fractionation:11 Gy per fraction x 5 fractions

Prescription dose: 11 Gy x 5F

Prescription isodose line:63% | Total beams: 118 IMRT to metastatic mediastinal lymph nodes (via linearaccelerator)

Consolidation immunotherapy initiated 4 weeks post-ra-diotherapy

Results and Follow-up      Near-complete resolution

\"8c97fdb6-799f-40f8-ae39-1a32fe71854c.png.png\"/

Early-Stage Lung Cancer or Pulmonary Oligometastases

65-year-old male with esophageal cancer pulmonary metastases, medically inoperable due to comorbidities.

Treatment Plan

Fractionation: 11 Gy per fraction x5 fractions | Prescription dose: 11 Gy x 5F

Prescription isodose line:63% | Total beams: 205

\"3635f2e2-f1c8-43d0-a26e-475a5aa2d3a5.png.png\"/

Results and Follow-up

Complete radiological resolution of the target lesion confirmed at1-month post-CyberKnife follow-up.

\"91777535-b7b7-4a8b-9e26-7a33e5090962.png.png\"/

11 Application of CyberKnife in Prostate Tumors

Treating Prostate CancerNo Surgery, Function-Sparing

\"169107b1-ec2a-4442-a14f-bbc9d0f53a5f.png.png\"/

Prostate cancer patients are not only concerned about thetreatment plan but are also worried about "embarrassingissues" in life or at work after treatment. CyberKnife treat-ment for prostate cancer requires no incision and no anes-thesia. During the procedure, the patient does not need toremove their trousers and can complete the treatmentsimply by lying flat on the treatment bed for 30 minutes.

\"ec9cccab-6602-4548-bbc7-eec99cf58ef7.png.png\"/

CyberKnife Treatment Celebrity Case

· High tumor control rate

· No incision, no blood loss; avoidspost-treatment issues like urinary incontinence

· Significantly reduces the incidence of sideeffects on sexual, urinary, and bowel functions

· Short treatment time: does not disruptdaily life during the treatment period

· Safe and effective; treatment can becompleted within 1-2 weeks

\"1ec39c40-7d48-4bc7-81fe-6f49d2e087b8.png.png\"/

Prostate Cancer Case Study 12

   Prostate Adenocarcinoma   

Male, 68 years old, was found to have a persistently elevated PSA for over a year. An MRl and prostatebiopsy confirmed prostate adenocarcinoma, Gleason Score 3+4=7 (Grade Group 2), with a PSA of 9.55ng/ml (intermediate-risk group). A PSMA PET/CT scan showed the lesion was confined to the prostaterulina out distant metastasis, in vune 2022, at the Foshan Cvberknite Center, the patient underwentdefinitive radiotherapy for prostate cancer using CyberKnife (SBRT). The treatment volume included theprostate and the proximal icm of the seminal vesicles.

Treatment Challenges

The patient had poor cardiac function with arrhythmia and refused Androgen Deprivation Therapy (ADT),surgery, and conventional follow-up. The location of the prostate is unique-close to the rectum and bladderwith a dense nerve supply. This requires extremely high precision in dose control and targeting to accuratelyirradiate the tumor while sparing adjacent organs and minimizing toxic side effects.

Treatment Plan

Fractionation: 7.25 Gy per fraction x5 fractions

Prescription dose: 7.25 Gyx5F  |  Prescription isodose line: 79%  |  Total beams: 86

\"b9252513-d6d9-4926-b012-d6db194b1630.png.jpg\"/

Results and Follow-up

the patient's PSA dropped to approximately 0.1 ng/ml. The treatment was well-tolerated and proceeded smoothly,leading to significant improvement in hiscondition. To date, no recurrence or toxicside effects have been reported.

   Prostate Cancer   

Male patient with low-volume oligometastatic castration-sensitive prostate cancer (cT2bNOM1b Stage IVB), featuring an isolated L4 vertebral metastasis. Baseline PSA 180.153 ng/ml, Gleason score 4+4=-8.

Treatment Plan

Systemic therapy: Long-term (2-3 years) androgen deprivation therapy

Local radiotherapy: Primary prostate lesion: SBRT with dose-painting technique and fiducial tracking;

Fractionation:7.25 Gy per fraction x5 fractions  |  Prescription dose: 7.25 Gy x 5F  |  Prescription isodose line:63%  |  Total beams: 273; L4 bone metastasis: Focal radiotherapy

\"9aab5cbb-993e-4e59-94ad-97c1f770b7b2.png.png\"/

13 Application of CyberKnife in Digestive System Tumors

Precision-Optimized

Digestive Function Preservation

\"31019648-0963-492c-b46a-1748a8f790ad.jpg\"

Protecting Normal Liver Tissue

Reducing Side Effects

The liver performs many vital functions. When treating livercancer, it is crucial to avoid damaging normal liver tissue.CyberKnife features real-time dynamic tracking and targetcorrection technology (Tracking), allowing the radiation beamsto precisely irradiate the moving tumor without affecting normal liver tissue.

For tumors that can be tracked using fiducial markers, this"precision-guided" tracking of the moving tumor allows forsmaller target volumes and higher radiation doses. This resultsin a better dose distribution within the target, maximallyreducing the impact on surrounding healthy tissues, therebylowering the risk of side effects and preserving liver function.

\"e5f65300-6cfd-40ca-a011-039e710b8f29.png.jpg\"/

Both the 2018 NCCN Guidelines and the 2018 American Association for the Study of Liver Diseases(AASLD) Guidelines indicate that SBRT can be an alternative treatment to radiofrequency ablation(RFA)/transarterial chemoembolization(TACE) forpatients with unresectable hepatocellular carcinoma(HCC). Previous clinical studies have shown that forpatients with early-stage liver cancer, SBRT can helpachieve a 5-year survival rate of 64%.

Clinical Trial:

A study by Daniel R. Wahl et al. from the University of Michigan Medical Center, published in the joural of Clinical Oncology (JCO) in 2016, compared treatment outcomes for 224 paients with inoperable small hepatocelllar carcinoma who received eitherradiofrequency ablation or SBRT. The 1-year and 2-year local control rates were 83.6% and 80.2% for RFA, versus 97.4% and 83.8% for SBRT, respectively. This indicates that SBRT provides a superior local control rate compared to RFA.

A study evalualing the ellicacv and oxicilv of SBRT in 57 paients with liver melastases showed that over 85% of paients achievedlocal tumor control within two years post-treatment, with no severe toxicity. The two-year overall survival rate was 55.9%.

Liver Tumor Case Study 14

Hepatocellular Carcinoma(HCC)

61-year-old male with chronic hepatitis B infection.  A 2.03x1.63 cm nodule in segment S5. Biopsy-confirmedwell-differentiated hepatocellular carcinoma. Serum AFP negative. Diagnosed as stage lA solitary HCC. Patient declined surgical intervention.

Treatment Plan

Fractionation: 12 Gy per fraction x5 fractions

Prescription dose: 12 Gyx5F | Prescription isodose line: 63% | Total beams: 148

\"94efc2ab-b1e7-4dfb-bfda-d9f9ce7c3497.png.png\"/\"a80ecd0c-bf27-48f8-9ba3-0b840b38ff3c.png.png\"/

15 Liver Tumor Case Study

Small Hepatocellular Carcinoma

63-year-old female with AFP-negative, PlVKA-l-positive clinical diagnosis of stage lA small HCC in segment S7. Biopsy deemed technically challenging. Management options included surveillance or surgery for the16-mm lesion. The patient declined both options and insisted on CyberKnife therapy.

Treatment Plan

Fiducial marker implantation for tracking

Fractionation: 12 Gy per fraction x5 fractions | Prescription dose: 12 Gy x 5F

Prescription isodose line: 65% | Total beams: 87

\"bb9b7454-7787-48da-99f5-4740999b5f79.png.png\"/

Results and Follow-up

\"c64c3752-0fd8-4e8e-99c7-8f812f2c98df.png.png\"/

Rectal Tumor Case Study 16

Locally Recurrent Rectal Cancer

58-year-old female with recurrent presacral adenocarcinoma (rT3NOM0 Stage llA) confirmed by imaging andpatholoay, 7 vears post-curative resection for primary mid-rectal moderately differentiated adenocarcinoma (pT1N0M0 Stage lA). Multidisciplinary team (MDT) consensus deemed surgical resection high-risk due to potential presacral venous plexus hemorrhage and inability to ensure negative margins, Recommended CyberKnife radiotherapy (11 Gy x 5F) to recurrent lesion plus CapeOX adjuvant chemotherapy.

Treatment Plan

Fractionation: 11 Gy per fraction x 5 fractions | Prescription dose: 11 Gy x 5F

Prescription isodose line: 68% | Total beams: 300

\"305e6538-95cf-4154-add3-0a6706098659.png.png\"/

Results and Follow-up

Complete response confirmed at 12-month post-radiotherapy follow-up.

\"962bea11-70e7-4544-9c47-a8bbf30483bf.png.png\"/

17 Application of CyberKnife in Pancreatic Tumors

CyberKnife Treatment for Pancreatic Cancer, lmproving Survival Rates & Relieving Pain

For over 80% of pancreatic cancer patients, surgery is not the best option. CyberKnife canovercome tumor displacement caused by factors like respiration and organ motion, ensuring theradiation beam remains precisely focused on the tumor lesion. This improves clinical outcomes (e.g., challenges in local control, frequent systemic metastasis), minimizes the risk of side effects, alleviates pain, enhances patient quality of life, and extends survival.

\"8056bd06-771f-4fd9-a516-fbed25a0f1b7.png.png\"/

Advantages of cyberknifefor Pancreatic cancer

· Can be used to shrink the size of pancreatic tumors toenable surgical resection

· Tracks and locks onto the tumor, providing a goodlocal control rate

· Low toxicity, reduces the risk of gastric or duodenalobstruction

· Can be used in combination with chemotherapy

· Painless and anesthesia-free, can be done as anoutpatient procedure

· Short treatment course, completed in 1-5 sessions

CyberKnife Treatment Celebrity Case

\"d6376096-4326-453e-ac1e-cc2b2af4b736.png.png\"/

Pancreatic Cancer Case Study 18

   Pancreatic cancer   

A mass was discovered in the patient's pancreas, with an AP dimension of 2.5cm. A biliary stent isvisible locally. Due to the involvement of the Superior Mesenteric Artery (SMA) and SuperiorMesenteric Vein (SMV), surgery could not be performed. The patient then underwent chemother.apy and CyberKnife treatment.

Treatment Plan

Fractionation: 8 Gy per fraction x 3 fractions

Prescription dose: 8 Gyx3F | Prescription isodose line: 81%

\"fdb66eb4-d8b1-44fc-8c88-32484522fc71.png.png\"/

Results and Follow-up

· Follow-up PET scan was negative, with the mass being indistinct.

· An 11-month post-treatment CT scan showed tumor shrinkage.

· 13 months after treatment, and 22 months after the initial symptoms appeared, the patient was pain-free.

19 CyberKnife Powerful Core Technologies





21 CyberKnife Treatment Indications

Indications   Applicable to most solid tumors throughout the body

\"e5f198c7-d434-4834-9747-d8a8470fef01.png.png\"/

Foshan CyberKnife Center Expert Team

Gathering International oncology Expertsto Achieve a Treatment Level Where 1+1>2

The Foshan CyberKnife Center is led by Dr. Jun Yang, the developer of North American CyberKnifequality control standards. The core team includes Professor Nianji Cui, a leading figure in radiotherapyin South China; Professor Enmin Wang, Former Director of CyberKnife Center at Huashan Hospital Affiliated to Fudan University; Professor Gang Ye, an internationally renowned medical oncologist; Professor Liangfu Han, former Department Vice Chair at Yale University's Department of Therapeutic Radiology; Director Qiuxia Lu, a national-level instructor for standardized radiation oncology training; Professor Bingguang Chen, recipient of the "Lingnan Famous Doctor" title in Guangdong Oncology; and senior radiotherapy experts Professor Wei Gong and Professor Xinzhi Lu. This team, with its international standards, extensive experience, and profound expertise, combined with top medicalphysicists and cutting-edge CyberKnife equipment, actualizes a synergistic "1+1 > 2" level of precisioncancer diagnosis and treatment, ensuring CyberKnife's maximum value is realized.

\"7103a09c-d42d-44f9-bce5-288ea949e222.png.png\"/

Major Mainstream Media Vying to Report

Official Launch of Foshan Chancheng Hospital CyberKnife Center in 2022 Reported by Multiple Media Outlets

\"f046dc28-09d0-42e7-8748-930946927fce.png.png\"/

Interview by Southern Television Guangdong (TvS)

\"7bd5b14d-0bfd-45c5-a940-3902972d5d4c.png.png\"/

Experience CyberKnife on Foshan TV's Famous Program "Xiaoqiang Hotline'

\"eecbb984-72bf-4f7d-8b51-5aa9ff2048c8.png.png\"/

Live Interview on Foshan TV's Famous Program "Hotline Face to Face'

\"0150ced8-7f47-4f8f-9dff-44c4d6315397.png.png\"/

Foshan's Exclusive CyberKnife Brings Great Innovation to Precision Cancer Treatment, Reported by Various Media Outlets

\"727be663-7b83-42a9-9356-a0c2074befc8.png.png\"/

Introduction to the Precision Oncology center

\"a0a1884a-c273-4d39-8f80-bd8dc36c4ff8.png.png\"/

Foshan Chancheng Hospital Precision Oncology Center

The Precision Oncology Center is a key discipline meticulously developed by Foshan Chancheng Hospital. Led bynumerous authoritative experts from both China and abroad, it fully adopts the clinical diagnosis and treatmentstandards and quality control criteria of top international oncology institutions. lt is a high-level center for cancerdiaanosis, treatment, and chronic cancer management that intecrates cancer prevention, early screening, diaanosistreatment, nursing, rehabilitation, nutrition, psychological support, education, research, and management.

First Chinese Paper to Receive Highest Honor from the International Radiosurgery Society

\"First

The paper submitted by Center Director Dr. Jun Yang and his team to the 2022 Annual Meeting of the International RadiosurgerySociety (RSS), titled "SCART Radiotherapy for Ultra-large, Recurrent,and Refractory Solid Tumors," won the "Best Paper of the Year"award with the highest score. This is believed to be the first time apaper from China has received such a prestigious honor at the RSS annual meeting.

First Asian Member of the International Radiosurgery Society (RSS)

\"First

After a rigorous selection process in 2021, our center became the first Asian institutional member ofthe International Radiosurgery Society (RSS).

Designated as the Chancheng District Cancer Prevention and Control Guidance Center

\"Designated

The Chancheng District Health Bureau designated our center as the Foshan Chancheng District Cancer Prevention and Control Guidance Center and established the Chancheng District Cancer Prevention and Control Center here.

Full-Cycle, One-Stop, Standardized Management

Characterized by "full-cycle management, one-stop service, and personalized, standardized, precision diagnosisand treatment." We provide patients with comprehensive disease management from screening to diagnosis, fromtreatment to rehabilitation, and from physical to psychological well-being, all through standardized multidisciplinary team (MDT) care. Through regular weekly remote consultations with international experts, patients can access cutting-edge global technologies and expert team resources and receive world-class medical care without having to travel abroad. As the first institutional member in Asia to be successfuly certified by and join the international Radiosurgery Society, the center stays current with the latest international clinical trends and actively participates incutting-edge international research.

\"bda8b0d2-fc83-4ad0-941d-496c4df2cf65.png.png\"/

\"afad98a4-fd5f-452a-af0e-ab8a61c41df4.png.png\"/

International Multidisciplinary Team (MDT) Model

Involving domestic and international experts with rich clinical experience to provide patientswith high-quality treatment plans.

The consulting experts are all from renowned oncology institutions at home and abroad. They possess many yearsof extensive clinical experience in cancer diagnosis and treatment, and serve patients using advanced medical concepts, cutting-edge techniques, and pharmaceuticals.


\"f1d2eefa-d11d-4383-9cc2-7ed39f97d3a7.png.png\"/

International MDT Model

This model has the experts "move" while the patient stays put. ltcreates a high-quality treatment plan by comprehensively considering opinions from all disciplines objectively and thoroughly. The multidisciplinary team works together to help the patient. medical concepts, cutting-edge techniques, and pharmaceuticals.

\"de7bc791-bd55-41f4-afb0-54fd4848827e.png.png\"/

Traditional Medical Model

In the traditional model, the patient runs between various specialized departments. The opinions from different departments are independent and fragmented, leaving the patient feeling isolated and helpless.

10 Major Cutting-Edge Cancer Treatment Technologies

\"a4b3195d-2f5c-4b52-aff7-919326954995.png.jpg\"/

CyberKnife Treatment

CyberKnife's unique six-dimensional (6D) robotic arm can select the optimal path to precisely irradiate the tumor, reducing side effects. Treatment can be completed in just 1-5 sessions.

\"a6d77654-a91d-4b01-b372-4439a3f26bea.png.jpg\"/

Precision Radiotherapy

Building upon conventional radiotherapy, this approach offers higher precision and a smaller radiation field, effectively reducing damage to surrounding normal tissues and significantly decreasing complications.

\"d76a7bd9-9585-46e6-86cf-d33f2a81427d.png.jpg\"/

PET/CT Diagnosis

The internationally advanced Siemens PET/CT scanner can acquire tomographic images of all parts of the body in a single scan, enabling the early detection of lesions and the diagnosis of diseases.

\"d89f55aa-f307-4eae-933c-e5a9a984698a.png.jpg\"/

International Multidisciplinary(MDT)Expert Consultation

Comprised of experts from radiotherapy, medical oncology, surgery,imaging, pathology, and other specialties. They conduct remote consultations with top US oncology experts to formulate treatment plans, allowing patients to receive international oncology medical services right at their doorstep.

\"fb99e8fe-c91e-478c-935b-cd771c673566.png.jpg\"/

Advanced Oncology Screening Technology

The affiliated Center for Advanced Cancer Screening pioneers cutting-edge detection methodologies, delivering comprehensive services including liquid biopsy, genomic tumor testing, tumor marker profiling, and immune function assessment. These address critical public health needs across symptom management, underlying condition control, nutritional intervention, and recurrence prevention during rehabilitation.

\"f05a8c79-0121-411d-976e-2131482f2e05.png.jpg\"/

Medical oncology

The Medical Oncology Department at Chancheng Hospital was established in 2008. lt is a National GCP (Good Clinical Practice) drug trial institution and a Ministry of Health model ward for standard-ized cancer pain treatment. The department is equipped with a variety of comprehensive cancer treatment facilities.

\"378b67c7-7923-4a0e-9fbd-25f14e3ef721.png.jpg\"/

CAR-T Cell Therapy

This is the first CAR-T cell therapy in China to be approved for marketing by the National Medical Products Administration (NMPA). lt is a therapeutic approach where a patient's own T-cells are modified through bioengineering to recognize and efficiently kill tumor cells.The first of its kind in Foshan!

\"805884e8-8096-4b6d-aa2b-91eb941603c3.png.jpg\"/

Tumor Treating Fields (TTFields) Therapy

A brand-new treatment technology for brain tumors. lt uses alternating electric fields to interfere with the mitosis (cell division) of cancer cells, causing them to undergo apoptosis (cell death) and inhibiting tumor growth. lt has minimal side effects.

\"12b0b265-82de-4f3d-b6cd-2b4e01066224.png.jpg\"/

Precision Oncology Laboratory

Foshan Fosun Chancheng Hospital's Precision Oncology Laboratory is guided by the precision medicine model. lt fully leveragesand integrates laboratory clinical and basic research, personalized diagnosis and treatment, and big data.

\"9446e0e8-7d5f-41b5-be5a-9f87b35e514c.png.jpg\"/

Comprehensive Cancer Care Continuum Management

The Oncology Rehabilitation and Integrated Management Center delivers comprehensive cancer care continuum management through coordinated medical-nutritional-immunological care. Key services: Multidisciplinary symptom control, Precision nutrition protocols, Cancer-chronic disease co-management, TCM/cellular therapy-based immunological restoration, within a recurrence-prevention framework.


","id":3,"imgs":"/cdn/2026-01/dee0f74d-852f-4c45-8e43-c3a28697a524.png","name":"CyberKnife","name2":" CyberKnife","rmks":"","sortid":"10000","sysCreateDate":"2025/07/03 19:03","sysCreateUid":"1","sysDeleted":"0","sysVid":"0","tindex":"1"},"result":"ok"}